Angio360 secures Commercial Evaluation License from the NIH
We are excited to announce that Angio360 successfully obtained a Commercial Evaluation License from the NIH of patents related to the detection of pathological angiogenesis and cancer. We are very pleased that the NIH believes in our ability to bring a much needed cancer diagnostic test to the market. Although this was a significant milestone for us, we are already looking forward to testing our proof of concept. We have high hopes that these tests will not only solidify our path moving forward, but also provide important information regarding our product development.